You may also like
A Review of Anti-Inflammatory Strategies in Cardiac Surgery
The overall conclusion is that although certain strategies reduce plasma levels of inflammatory mediators, convincing evidence of significant clinical benefits is yet to come.
1 min read
The Future:Therapy of Myocardial Protection
Recent studies have proposed that old, inexpensive drugs--in human use for decades (e.g., β-blockers and cyclosporine, among others)--can reduce ischemia/reperfusion injury, I/R injury, when administered intravenously before coronary opening. The demonstration of such a cardioprotective effect should have a significant impact in the care of AMI patients.
1 min read
Comparison of Ringer’s Lactate and Plasmalyte-A as Cardiopulmonary Bypass Prime for Bypass Associated Acidosis in Valve Replacement Surgeries
Patients who received Plasmalyte-A as cardiopulmonary bypass prime developed less metabolic acidosis. Hence we conclude that Plasmalyte-A is the preferred cardiopulmonary bypass prime in adult patients undergoing valve replacement surgerie
1 min read